why choose us

First received: March 10, 2023

Clinical Trial: Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Study Status: Completed

Recruit Status: RECRUITING

Condition: HNSCC

Study Type: INTERVENTIONAL


Official Title: An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Brief Summary: Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with recurrent/metastatic (R/M) HNSCC.Two-thirds of patients will be randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to receive pembrolizumab alone.

Read more